PTC Therapeutics, Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
PTC Therapeutics, Inc. (PTCT) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $24.79 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-07-30
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $24.79M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $34.70M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $9.28M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $9.38M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $24.79M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $34.70M 10-Q · filed 2026-05-07 |
| 2025-09-30 | $9.28M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $9.38M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $11.37M 10-Q · filed 2025-05-06 |
| 2024-09-30 | $3.04M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $5.72M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $8.18M 10-Q · filed 2024-04-25 |
| 2023-09-30 | $58.64M 10-Q · filed 2023-10-26 |
| 2023-06-30 | $94.81M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $118.27M 10-Q · filed 2023-04-27 |
| 2022-09-30 | $31.41M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $52.73M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $70.47M 10-Q · filed 2022-05-03 |
| 2021-09-30 | $14.41M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $25.50M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $33.83M 10-Q · filed 2021-05-04 |
| 2020-09-30 | $9.63M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $17.46M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $23.85M 10-Q · filed 2020-04-30 |
| 2019-09-30 | $7.03M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $13.27M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $18.21M 10-Q · filed 2019-05-02 |
| 2018-09-30 | $5.79M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $11.24M 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |